Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0F57T | ISIN: JP3475350009 | Ticker-Symbol: D4S
Tradegate
24.04.25
20:50 Uhr
21,120 Euro
-0,190
-0,89 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
DAIICHI SANKYO CO LTD Chart 1 Jahr
5-Tage-Chart
DAIICHI SANKYO CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
21,51021,79008:09
21,48021,80008:09

Aktuelle News zur DAIICHI SANKYO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DAIICHI SANKYO Aktie jetzt für 0€ handeln
MiAstraZeneca/Daiichi Sankyo's Enhertu shows promise in first-line HER2-positive breast cancer4
MoAstraZeneca & Daiichi Sankyo's Enhertu Posts Positive Data as First-Line Breast Cancer Therapy4
MoAstraZeneca, Daiichi say Enhertu delivers 'highly statistically significant' efficacy in first-line breast cancer3
MoAstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients4
MoDaiichi Sankyo, AstraZeneca's Enhertu Plus Pertuzumab Shows Positive Results In Breast Cancer Trial401LONDON (dpa-AFX) - Daiichi Sankyo Co., Ltd. (DSKYF.PK) announced Monday that Enhertu (trastuzumab deruxtecan), co-developed and commercialized with British drug major AstraZeneca Plc. (AZN.L...
► Artikel lesen
MoDaiichi Sankyo: ENHERTU Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer358DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca's ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2 positive metastatic patient...
► Artikel lesen
10.04.AstraZeneca/Daiichi Sankyo's Datroway approved by EC to treat breast cancer9
08.04.Daiichi Sankyo and AstraZeneca get EU approval for Datroway12
08.04.AZ, Daiichi get EU okay for breast cancer drug Datroway3
08.04.Daiichi Sankyo: DATROWAY Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer326First approval in the EU for Daiichi Sankyo and AstraZeneca's DATROWAY based on TROPION-Breast01 trial showing 37% reduction in the risk of disease progression or death versus chemotherapy ...
► Artikel lesen
04.04.Daiichi and AstraZeneca's Enhertu gains EC approval for breast cancers9
04.04.AstraZeneca/Daiichi Sankyo's Enhertu receives EC approval for HER2-low breast cancer3
04.04.AstraZeneca And Daiichi Sankyo's Enhertu Approved In EU For Advanced Breast Cancer Treatment408LONDON (dpa-AFX) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced...
► Artikel lesen
04.04.Daiichi Sankyo: ENHERTU Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy367Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval...
► Artikel lesen
28.03.Dividendenbekanntmachungen (28.03.2025)21.970 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ABERDEEN GROUP PLC ADR  US00108N1000  0,3716 USD  0,3442 EUR  ACOM CO LTD  JP3108600002  7 JPY  0,0429 EUR  ADVANEX INC  JP3213400009  20...
► Artikel lesen
11.03.Daiichi taps Nosis to deliver RNA therapies beyond the liver21
04.03.DelveInsight Business Research, LLP: Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight655On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places...
► Artikel lesen
04.03.DelveInsight Business Research, LLP: Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight729On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places...
► Artikel lesen
03.03.AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer17
03.03.Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment20
Seite:  Weiter >>
113 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1